BioSpace News Archive

Provention Bio, Inc. today announced that the Company has appointed Christina Yi as Chief Operations Officer, responsible for manufacturing, supply chain and human resources, and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality.

Arrowhead Pharmaceuticals, Inc. announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, which is planned to be the site of an approximately 140,000 square foot drug manufacturing facility and an approximately 115,000 square foot laboratory and office facility to support process development and analytical activities.

Achilles Therapeutics plc announced that the Company has been added to the NASDAQ Biotech Index, effective prior to market open, Monday, December 20, 2021.

FibroGen, Inc. and HiFiBiO Therapeutics announced an extension of their partnership with FibroGen’s exercise of an exclusive license option for HiFiBiO’s anti-CCR8 monoclonal antibody program.

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced strategic leadership changes and a new governance initiative designed to facilitate its global pipeline development and accelerate its ongoing transformation towards an integrated global biopharma company.

Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), is pleased to announce it has entered into a definitive agreement (the “Definitive Agreement”) to acquire (the “Acquisition”) all of the outstanding securities of Spore Life Sciences Inc. (“Spore”).

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), today announced that it received notification from the European Patent Office (the “EPO”) of an intention to grant a patent for IceCure’s application entitled “Cryogen Pump”.

Kriya Therapeutics, Inc. today announced the appointment of Neera Ravindran, M.D., M.B.A., as Chief Financial Officer.

bluebird bio, Inc . (NASDAQ: BLUE) today announced that the FDA has placed its clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD) on partial clinical hold for patients under the age of 18.

Twist Bioscience Corporation today announced the launch of the Twist 96-Plex Library Prep Kit, a high-performance, cost-effective preparation kit for next-generation sequencing (NGS).